SWEET: Once Daily Truvada Versus Twice Daily Combivir for the Treatment of HIV Infection

HIV Infections Clinical Trial

Official title:

A Phase 3, Open Label, Randomised, Parallel Group Study to Compare the Effect on Prevention and Resolution of Treatment Related Adverse Events of a Simplified, Once Daily Regimen of a Fixed Dose Combination Tablet of Emtricitabine and Tenofovir DF Versus Twice Daily co-Formulated Zidovudine and Lamivudine (Combivir®) or Zidovudine and Lamivudine, in Virologically Suppressed, HIV Infected Patients Taking Efavirenz

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00323544
• Other study ID #: GS-MC-164-0111
• Status: Completed
• Phase: Phase 3
• First received: May 5, 2006
• Last updated: June 30, 2008
• Start date: October 2004
• Est. completion date: October 2007

Study information

• Verified date: June 2008
• Source: Gilead Sciences
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency
• Study type: Interventional

Clinical Trial Summary

This study will investigate whether the simplified regimen of a once daily fixed dose combination of Truvada (emtricitabine and tenofovir disoproxil fumarate [DF]) will be associated with a reduced rate of adverse events, seen with long term use of antiretrovirals, as well as improved adherence compared to a twice daily fixed dose combination of Combivir.

Description:

The success of HAART is largely dependant on an individual's ability to adhere strictly to an antiretroviral regimen. Regimen characteristics that affect adherence include dosing frequency and pill burden. Several studies have shown improved adherence with lower pill burden and a meta-analysis of the virological outcome in relation to pill burden has shown a significant correlation between lower pill burden and better virological outcome. A systematic review of studies across a range of medical specialties demonstrated that once daily therapy improves adherence relative to more frequent dosing although statistical significance was not demonstrated relative to twice daily regimens.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 220
• Est. completion date: October 2007
• Est. primary completion date: June 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients of either sex aged > 18 years.

2. HIV positive.

3. Stable antiretroviral therapy consisting of efavirenz (EFV) given with Combivir® or zidovudine (AZT) + lamivudine (3TC) for at least 6 months.

4. Patients with viral loads < 50 copies/ml on last 2 consecutive tests and < 400 copies/ml for > 3 months.

5. Patients requiring a lipid lowering agent must be established on a stable dose/frequency for at least 12 weeks prior to Baseline and be expected to continue on stable dose/frequency for the duration of the study.

6. Negative serum pregnancy test (females of childbearing potential only).

7. Willingness to use effective contraception (such as barrier or coil methods) by both males and females while on study treatment and for 30 days following study drug completion.

8. The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.

Exclusion Criteria:

1. Pregnant or lactating female.

2. History of AZT monotherapy.

3. Use of anabolic steroids, with the exception of testosterone for documented hypogonadism, within 90 days prior to the Baseline visit.

4. Documented parvovirus infection.

5. Use of erythropoietin within the last six weeks.

6. Patients who have had a blood transfusion in the last six weeks.

7. Karnofsky score < 50.

8. Prior history of significant renal disease.

9. Prior history of osteopenia/osteoporosis.

10. Creatinine clearance < 60mL/min.

11. AST/ALT > 5 x upper limits of normal (ULN).

12. Previous adefovir dipivoxil or cidofovir therapy.

13. Known history of resistance (including primary resistance) to any of the study medications - tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), AZT, 3TC, or EFV.

14. Patients receiving ongoing therapy with any of the following (administration of any of the following medications must be discontinued at least 30 days prior to the Baseline visit and for the duration of the study period):

• Nephrotoxic agents

• Probenecid

• Systemic chemotherapeutic agents (i.e. cancer treatment medications)

• Systemic corticosteroids

• Interleukin 2 (IL 2)

• Drugs that interact with efavirenz

• Dihydroergotamine

• Ergotamine

• Midazolam

• Triazolam

• Cisapride

• Rifampin

• Ergonovine

• Methylergonovine

15. Patients with known hypersensitivity to any of the study medications or excipients.

16. Active, serious infections (other than HIV-1 infection) requiring parenteral antibiotic therapy within 15 days prior to Screening.

17. Patients who are currently taking part in any other clinical trial or have taken part in a clinical trial of a new chemical entity within 1 month prior to Screening.

18. Any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the dosing requirements.

19. Patients with cancer (except basal cell carcinoma).

20. Co-infection with hepatitis B virus

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Acquired Immunodeficiency Syndrome
• HIV Infections
• Infection

Intervention

Drug:
• zidovudine and lamivudine (Combivir®)

• emtricitabine and tenofovir DF

Locations

Country	Name	City	State
United Kingdom	Gilead Sciences	Cambridge

Sponsors (1)

Lead Sponsor	Collaborator
Gilead Sciences

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.
Secondary	The secondary endpoints in this study include: Change from baseline in absolute haemoglobin at Week 48
Secondary	Lipids profile: change from baseline in total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), TC/HDL, and triglyceride (TG)
Secondary	Quality of life (QoL)
Secondary	Measures of treatment adherence (Medication Adherence Self-Report Survey [MASRI] questionnaire)
Secondary	Measures of regimen intrusiveness (HIS and Brief Medication Questionnaire [BMQ])
Secondary	Changes in markers of body composition from dual energy x-ray absorptiometry (DEXA) scans (a sub-study)
Secondary	HIV RNA: proportion of patients with HIV ribonucleic acid (RNA) < 400 copies/mL; proportion of patients with HIV RNA < 50 copies/mL and change from baseline in log10 copies/mL at Weeks 24 and 48
Secondary	CD4: change from baseline in CD4 counts
Secondary	Treatment adherence and acceptability
Secondary	Use of lipid lowering drugs (number of patients and duration of use)
Secondary	Adverse events (AEs): AEs will be coded and the coded terms will be used to summarize the count of patients with any event, intensity of each event (highest intensity will be used if an event is reported more than once by a patient) and relationship to:
Secondary	Other lab tests: results at baseline and changes from baseline